[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR047070A1 - Derivados de difenilazetidona - Google Patents

Derivados de difenilazetidona

Info

Publication number
AR047070A1
AR047070A1 ARP040104864A ARP040104864A AR047070A1 AR 047070 A1 AR047070 A1 AR 047070A1 AR P040104864 A ARP040104864 A AR P040104864A AR P040104864 A ARP040104864 A AR P040104864A AR 047070 A1 AR047070 A1 AR 047070A1
Authority
AR
Argentina
Prior art keywords
difenilazetidona
derivatives
solvates
compounds
salts
Prior art date
Application number
ARP040104864A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34714057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0329780A external-priority patent/GB0329780D0/en
Priority claimed from SE0401907A external-priority patent/SE0401907D0/xx
Priority claimed from SE0402785A external-priority patent/SE0402785D0/sv
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR047070A1 publication Critical patent/AR047070A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen compuestos de la formula (1) (en donde los grupos variables se definen segun lo descripto), sales farmacéuticamente aceptables, solvatos, solvatos de dichas sales y profármacos de dichos compuestos, y su uso como inhibidores de la absorcion del colesterol para el tratamiento de hiperlipidemia. Además se describen procesos para su elaboracion y composiciones farmacéuticas que los contienen.
ARP040104864A 2003-12-23 2004-12-22 Derivados de difenilazetidona AR047070A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0329780A GB0329780D0 (en) 2003-12-23 2003-12-23 Chemical compounds
SE0401907A SE0401907D0 (sv) 2004-07-21 2004-07-21 Chemical compounds
SE0402785A SE0402785D0 (sv) 2004-11-15 2004-11-15 Chemical compunds

Publications (1)

Publication Number Publication Date
AR047070A1 true AR047070A1 (es) 2006-01-04

Family

ID=34714057

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104864A AR047070A1 (es) 2003-12-23 2004-12-22 Derivados de difenilazetidona

Country Status (15)

Country Link
US (1) US7871998B2 (es)
EP (1) EP1699759B1 (es)
JP (1) JP4688819B2 (es)
AR (1) AR047070A1 (es)
AT (1) ATE485267T1 (es)
AU (1) AU2004303742B2 (es)
BR (1) BRPI0418004A (es)
CA (1) CA2550215A1 (es)
DE (1) DE602004029715D1 (es)
IL (1) IL176158A0 (es)
NO (1) NO20062591L (es)
SA (1) SA04250427A (es)
TW (1) TW200526572A (es)
UY (1) UY28695A1 (es)
WO (1) WO2005061452A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2403848A1 (en) 2009-03-06 2012-01-11 Lipideon Biotechnology AG Pharmaceutical hypocholesterolemic compositions
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW223059B (es) * 1991-07-23 1994-05-01 Schering Corp
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CZ7696A3 (en) 1993-07-09 1996-04-17 Schering Corp Process for preparing azetidinone
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
AU2943095A (en) 1994-06-20 1996-01-15 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996009827A2 (en) 1994-09-20 1996-04-04 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
AR004701A1 (es) 1995-10-31 1999-03-10 Schering Corp 2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo.
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
ES2244238T3 (es) 1998-12-07 2005-12-01 Schering Corporation Proceso para la sintesis de azetidinonas.
DK1140187T3 (da) 1998-12-23 2003-12-22 Searle Llc Kombinationer af en IBAT-inhibitor og en MTP-inhibitor til cardiovaskulære indikationer
CN1249250C (zh) 1999-04-05 2006-04-05 先灵公司 用于制备1－(4－氟苯基)－3(R)－[3(S)－羟基－3－(4－氟苯基)丙基]－4(S)－(4－羟苯基)－2－β丙内酰胺的立体选择性微生物还原反应
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
DE10042447A1 (de) 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
ATE279425T1 (de) 2000-12-20 2004-10-15 Schering Corp Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
ATE338039T1 (de) * 2000-12-21 2006-09-15 Sanofi Aventis Deutschland Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN1217927C (zh) 2000-12-21 2005-09-07 阿文蒂斯药物德国有限公司 新的1,2－二苯基氮杂环丁烷酮、其制备方法、含有所述化合物的药物及其在治疗脂质代谢病症中的应用
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
EP1353695A2 (en) 2001-01-26 2003-10-22 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
ES2296894T3 (es) 2001-01-26 2008-05-01 Schering Corporation Combinaciones de ezetimiba con aspirina para tratar estados vasculares.
CN100522159C (zh) 2001-01-26 2009-08-05 先灵公司 取代的氮杂环丁烷酮化合物在制备治疗谷甾醇血症的药物中的应用
RS20100015A (en) 2001-01-26 2010-12-31 Schering Corporation Combination of receptor activator activated by fenofibrate peroxisome-proliferator (ppar) with sterol absorption inhibitor ezetimibe for vascular indications
DK1385548T3 (da) 2001-01-26 2007-09-10 Schering Corp Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
WO2002058733A2 (en) 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
EP1389114A2 (en) 2001-03-08 2004-02-18 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
CA2447884A1 (en) 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2003026643A2 (en) 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002572A (es) * 2001-09-21 2004-05-31 Schering Corp Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
AU2003225027A1 (en) 2002-04-16 2003-11-03 Merck And Co., Inc. Combination therapy using a ppar alpha/gamma agonist
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US6761509B2 (en) * 2002-07-26 2004-07-13 Jan Erik Jansson Concrete module for retaining wall and improved retaining wall
CN1678296A (zh) 2002-07-30 2005-10-05 卡里凯昂公司 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
US6960047B2 (en) * 2002-08-02 2005-11-01 Innovative Technology Application, Inc. Protection barrier apparatus
RU2345089C2 (ru) 2002-08-06 2009-01-27 Санофи-Авентис Дойчланд Гмбх ОЧИЩЕННЫЙ 145 кДа-БЕЛОК, СПОСОБНЫЙ СВЯЗЫВАТЬ ХОЛЕСТЕРИН И/ИЛИ ИНГИБИТОРЫ ПОГЛОЩЕНИЯ ХОЛЕСТЕРИНА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ОЧИСТКИ И ПРИМЕНЕНИЕ 145 кДа-БЕЛКА
EP1560579A1 (en) 2002-11-06 2005-08-10 Schering Corporation Cholesterol absorption inhibitors for the treatment of autoimmune disorders
MXPA05009503A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1626954A2 (en) 2003-05-05 2006-02-22 Ranbaxy Laboratories, Ltd. Process for the preparation of trans-isomers of diphenylazetidinone derivatives
WO2004107958A2 (en) 2003-05-30 2004-12-16 Schering Corporation Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
US7002008B2 (en) * 2003-06-16 2006-02-21 Bomi Patel Framroze Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1660456A2 (en) 2003-08-25 2006-05-31 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
US20070135357A1 (en) 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
MXPA06005106A (es) 2003-11-10 2007-01-25 Microbia Inc 4-biarilil-1-fenilazetidin-2-onas.
US7067675B2 (en) 2003-11-24 2006-06-27 Hetero Drugs Limited Process for ezetimibe intermediate
CA2548790A1 (en) 2003-12-17 2005-06-30 Dainippon Sumitomo Pharma Co., Ltd. Medicinal compositions and combinations
JP2007516287A (ja) 2003-12-23 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血症化合物
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US20050171080A1 (en) 2003-12-23 2005-08-04 Dr. Reddy's Laboratories, Inc. Polymorphs of ezetimibe and process for preparation thereof
WO2005066120A2 (en) 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives
CA2553769C (en) 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
AP2006003832A0 (en) 2004-01-20 2006-12-31 Panacea Biotec Ltd Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
DE102004025072A1 (de) 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
AR049184A1 (es) 2004-05-21 2006-07-05 Aventis Pharma Gmbh Procedimiento para la preparacion de derivados de 1, 4 - difenilazetidinona en presencia de agentes de sililacion y de un catalizador de ciclacion
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
SI1831162T1 (sl) 2004-12-20 2013-03-29 Merck Sharp & Dohme Corp. Postopek sinteze azetidinonov
IL166149A0 (en) 2005-01-05 2006-01-15 Hadasit Med Res Service Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
EP1851197A2 (en) 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
WO2006102674A2 (en) 2005-03-24 2006-09-28 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
MX2007012253A (es) 2005-04-04 2007-12-07 Univ Pontificia Catolica Chile Uso de ezetimibe para la prevencion y tratamiento de calculos de colesterol en la via biliar.
JP2008539255A (ja) 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
EP1885703A4 (en) 2005-05-11 2009-09-02 Microbia Inc METHODS FOR PRODUCING 4-BIPHENYLYLAZETIDIN-2-ONE PHENOLIC DERIVATIVES
TW200740752A (en) 2005-05-13 2007-11-01 Microbia Inc 4-Biarylyl-1-phenylazetidin-2-ones
CA2609506A1 (en) 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
CA2611142A1 (en) 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
WO2006134604A1 (en) 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057380A1 (es) 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057383A1 (es) 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US8013150B2 (en) 2005-06-22 2011-09-06 Msn Laboratories Ltd. Process for the preparation of ezetimibe
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR056866A1 (es) 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007015161A1 (en) 2005-08-01 2007-02-08 Warner-Lambert Company Llc Novel substituted azetidinones
WO2007016643A2 (en) 2005-08-01 2007-02-08 Mount Sinai School Of Medicine Of New York University A method for extending longevity using npc1l1 antagonists
WO2007017705A1 (en) 2005-08-09 2007-02-15 Glenmark Pharmaceuticals Limited Process for the preparation of azetidinones
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
MX2007005493A (es) 2005-09-08 2007-09-11 Teva Pharma Procesos para la preparacion de (3r,4s)-4-((4-benciloxi)fenil)-1- (4-fluorofenil)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil-2- azetidinona, un intermedio para la sintesis de ezetimibe.
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
TW200803868A (en) 2005-11-15 2008-01-16 Takeda Pharmaceutical Novel method for treating hyperlipidemia
DE102005055726A1 (de) 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7498431B2 (en) * 2005-12-01 2009-03-03 Bomi Patel Framroze Process for the preparation of chiral azetidinones
HUP0501164A2 (en) 2005-12-20 2007-07-30 Richter Gedeon Nyrt New industrial process for the production of ezetimibe
WO2007075702A2 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
JPWO2008108486A1 (ja) * 2007-03-06 2010-06-17 帝人ファーマ株式会社 １−ビアリールアゼチジノン誘導体
US7624915B2 (en) * 2008-02-04 2009-12-01 Riverwest Engineering & Design, Inc. Recycling center

Also Published As

Publication number Publication date
IL176158A0 (en) 2006-10-05
JP4688819B2 (ja) 2011-05-25
EP1699759A1 (en) 2006-09-13
BRPI0418004A (pt) 2007-04-17
WO2005061452A8 (en) 2006-04-06
EP1699759B1 (en) 2010-10-20
CA2550215A1 (en) 2005-07-07
UY28695A1 (es) 2005-07-29
WO2005061452A1 (en) 2005-07-07
JP2007516280A (ja) 2007-06-21
SA04250427A (ar) 2005-12-03
ATE485267T1 (de) 2010-11-15
AU2004303742A1 (en) 2005-07-07
TW200526572A (en) 2005-08-16
US20080064676A1 (en) 2008-03-13
US20100099657A2 (en) 2010-04-22
DE602004029715D1 (de) 2010-12-02
US7871998B2 (en) 2011-01-18
AU2004303742B2 (en) 2008-06-19
NO20062591L (no) 2006-09-20

Similar Documents

Publication Publication Date Title
AR047070A1 (es) Derivados de difenilazetidona
UY28691A1 (es) Derivados de difenilazetidona
UY29614A1 (es) Compuestos químicos
UY27882A1 (es) Compuestos quimicos
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
UY29607A1 (es) Compuestos quimicos
ECSP078053A (es) Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia
UY28510A1 (es) Compuestos quimicos
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY28342A1 (es) Nuevos compuestos
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
ECSP10010561A (es) Pirimidin-5-carboxamidas sustituidas 281
UY27516A1 (es) Bencimidazoles
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
ECSP088246A (es) Nuevos derivados de benzotiazolona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal